ABIOMED INC

Form 4

February 24, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB

OMB APPROVAL

Number:

5. Relationship of Reporting Person(s) to

(Check all applicable)

Issuer

3235-0287 January 31,

2005

0.5

Expires:

Estimated average burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

ABIOMED INC [ABMD]

Symbol

1(b).

(Print or Type Responses)

TERMEER HENRI A

1. Name and Address of Reporting Person *

					(Check an applicable)							
(Last) (First) (Middle) C/O ABIOMED, INC., 22 CHERRY HILL DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 02/22/2011										
							X Director Officer (give below)		0% Owner other (specify			
		(Street)		4. If An	nendment,	Date Orig	inal		6. Individual or Joint/Group Filing(Check			
` '			Filed(Month/Day/Year)					Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
	DANVER	S, MA 01923							Person			
	(City)	(State)	(Zip)	Tal	ble I - Non	-Derivati	ve Sec	curities Acqu	uired, Disposed o	of, or Benefic	ially Owned	
	1.Title of Security (Instr. 3) Common Stock, \$0.01 par value	2. Transaction Date (Month/Day/Year)		Date, if	Code (Instr. 8)	4. Secur owr Dispo (Instr. 3,	esed of 4 and (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Common Stock, \$0.01 par value	02/22/2011			S	200	D	\$ 13.02 (6)	1,827,380	I	by Genzyme Corporation	
	Common Stock, \$0.01 per value	02/22/2011			S	8,018	D	\$ 12.8919 (7)	1,819,362	I	by Genzyme Corporation	

Edgar Filing: ABIOMED INC - Form 4

Common Stock, \$0.01 par	02/23/2011	S	3,436	D		1,815,296	I	by Genzyme Corporation
\$0.01 par	02/23/2011	5	3,430	D	(8)	1,013,270	•	(3)
value								

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

(Ir

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) (1)	\$ 19.69					08/09/2001(2)	08/09/2010	Common Stock	5,000
Stock Option (right to buy) (1)	\$ 18.4					08/08/2002(2)	08/08/2012	Common Stock	5,000
Stock Option (right to buy) (1)	\$ 4.71					08/06/2003(2)	08/06/2013	Common Stock	5,000
Stock Option (right to buy) (1)	\$ 5.15					08/13/2004(2)	08/13/2014	Common Stock	5,000
Stock Option (right to buy) (4)	\$ 10.41					08/11/2005(2)	08/11/2014	Common Stock	8,000

Edgar Filing: ABIOMED INC - Form 4

Stock Option (right to buy) (4)	\$ 10.06	08/09/2006 ⁽²⁾	08/10/2015	Common Stock	8,000
Stock Option (right to buy) (4)	\$ 13.21	08/08/2007 <u>(2)</u>	08/09/2016	Common Stock	8,000
Stock option (right to buy) (4)	\$ 12.69	08/13/2008 <u>(2)</u>	08/08/2017	Common Stock	8,000
Stock Option (right to buy) (5)	\$ 18.63	08/12/2009 <u>(2)</u>	08/13/2018	Common Stock	8,000
Stock Option (right to buy) (5)	\$ 7.67	08/11/2010 <u>(2)</u>	08/12/2019	Common Stock	12,000
Stock Options (right to buy) (5)	\$ 9.99	08/10/2011	08/11/2020	Common Stock	12,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
r	Director	10% Owner	Officer	Other			
TERMEER HENRI A C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923	X						
Signatures							

Signatures

/s/ Ian W. McLeod (by power of attorney)

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors.
- (2) This option becomes exercisable in full on the date set forth in Table II, Column 6.

Reporting Owners 3

Edgar Filing: ABIOMED INC - Form 4

- The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purposes. The reporting person is the Chief Executive Officer of Genzyme Corporation.
- (4) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- (5) Grant to reporting person of option to buy shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$12.85 (6) and \$13.02. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$12.85 (7) and \$12.93. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between (8) \$12.75and \$12.845. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.